KEYNOTE-006: Results and Relevance

The NCCN update adds locally advanced CSCC to the category 2A listing that cosibelimab received for metastatic disease in 2025.

Phase 1 data support continued investigation of roginolisib in advanced cancers, including metastatic uveal melanoma.

The CHMP opinion supports 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks; a European Commission decision is expected in the coming months.

New severe treatment-related adverse effects after discharge from lifileucel therapy were uncommon and emerged across several months.

Patients with resected RCC given adjuvant durvalumab with or without tremelimumab described persistent low-grade toxicities as most disruptive to QOL.

Tenumomeran/raplemomeran plus pembrolizumab missed the PFS end point in HPV16-positive HNSCC.